Muriel D'Ambrosio

Citigroup Global Markets, Inc. (Broker) (CGMI-Broker) is the broker/dealer division of Citigroup Global Markets, Inc., an investment bank headquartered in New York City with additional offices across the US. The firm was founded in 2004 and is a subsidiary of Citigroup Financial Products, Inc., ultimately held by Citigroup, Inc. (NYSE: C). CGMI-Broker covers all market capitalizations of the major global indices and provides macro and quantitative analysis of global markets and sector trends. Their core focus of the group is to help investing clients make informed decisions by providing value-added, independent, insightful analysis.

Lazard Frères Gestion SAS is an investment management firm headquartered in Paris, France. The firm was founded in 1995 and is a subsidiary of Lazard Group LLC, which is owned by Lazard Ltd. (NYSE: LAZ) in the US. They provide asset management and advisory services for individual and institutional clients.

Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco.

Exane SA (Broker) (Exane) is the brokerage division of Exane SA, itself a subsidiary of Verner Investissements SAS in France. Established in 2004 as a joint venture between BNP Paribas and Verner Investissements, the firm is based in Paris and specializes in European equity research and broking activities. Exane has research centers in Paris and London which are supported by a team of economists and strategists.

Abu Dhabi Investment Authority (Investment Management) (ADIA-IM) is the sovereign wealth fund management division of state-owned Abu Dhabi Investment Authority in UAE. The firm was founded in 1976 and is headquartered in Abu Dhabi. ADIA-IM invests fund on behalf of the Government of Abu Dhabi with a focus on long-term value creation. They also manage a global investment portfolio that is diversified across more than two dozen asset classes and sub-categories.

Amundi Asset Management SA (Investment Management) (Amundi-IM) is the investment management division of Amundi Asset Management SA, ultimately held by SAS Rue la Boétie’s Crédit Agricole SA (EPA: ACA, ADR: CRARY) in France. It was founded in 2010 when the asset management operations of Crédit Agricole SA and Société Générale merged. Headquartered in Paris, the firm develops products for institutional clients and third-party distributors and has ties with sovereign wealth funds, pension funds, institutional funds and corporate funds. They have distribution agreements with platforms in Europe and Asia. Amundi-IM is a signatory to the United Nations Principles of Responsible Investing (UNPRI).

Econocom France designs, finances and oversees the digital transformation of organizations. It offers sourcing, deployment and installation, assistance and advice, delivery, recycling, and dedicated storage. The firm services include clouds and data centers, end user environment, networks and security, applications, and data intelligence. The company was founded by Jean-Louis Bouchard in 1974 and is headquartered in Clichy, France.

LimFlow SA develops and offers medical devices which transformes the treatment of critical limb Ischemi. The firm?s proprietary and CE marked technology is a novel and purely percutaneous therapy for ?no-option? CLI patients. The company was founded by Martin T. Rothman in 2012 and is headquartered in Paris, France.

Cytoimmune Therapeutics, Inc. is a clinical-stage biotechnology company founded in 2017 and based in Toa, Japan. The American company is focused on developing a pipeline of NK cell therapies for various types of cancer, including lung cancer, acute myeloid leukemia, solid tumors, and multiple myeloma. The private company's lead product, Cyto-102, is a track-NK cell therapy that aims to enter clinical trials in combination with atezolizumab for non-small cell lung cancer in 2022. Cytoimmune Therapeutics also offers cell therapy development and clinical manufacturing services to biotechnology companies and academia. The company's state-of-the-art clinical cell manufacturing facility is custom-built to support the development and commercialization of cutting-edge T cell or NK cell therapies. The company was founded in 2017 by Michael A. Caligiuri, William Michael Rosellini, and Jianhua Yu, Ph.D. José Eduardo Vidal has been the CEO of the company since 2021.